1-3 of 3
Bercedis Peterson, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Impact of Age on Outcomes Following Initial Therapy with Various Chemotherapy and Chemoimmunotherapy Regimens in Patients with Chronic Lymphocytic Leukemia (CLL): Results of CALGB Studies

Jennifer A. Woyach, MD, Amy S. Ruppert, MAS, Bercedis Peterson, PhD, MS, Kanti R. Rai, M.D., Thomas S. Lin, MD, PhD, Frederick R. Appelbaum, MD, Martin S. Tallman, MD, Andrew R Belch, MD, Richard A. Larson, MD, John C. Byrd, MD
Journal: Blood
Blood (2011) 118 (21): 289.
https://doi.org/10.1182/blood.V118.21.289.289
Published: 2011
Journal Articles

Alemtuzumab Consolidation Does Not Improve Outcome for CLL Patients with High Risk Genomic Features on Successive CALGB Trials.

Jeffrey A. Jones, MD, MPH, Amy Stark, MAS, Weiqiang Zhao, MD PhD, Thomas S. Lin, MD, PhD, Kanti R Rai, MD, Guido Marcucci, MD, Bercedis Peterson, PhD, MS, Richard A. Larson, MD, Nyla A. Heerema, PhD, John C. Byrd, MD
Journal: Blood
Blood (2011) 118 (21): 1791.
https://doi.org/10.1182/blood.V118.21.1791.1791
Published: 2011
Journal Articles

Select High Risk Genetic Features Predict Earlier Progression Following Chemoimmunotherapy with Fludarabine and Rituximab in Chronic Lymphocytic Leukemia (CLL): Preliminary Justification for Risk-Adapted Therapy.

John C. Byrd, MD, John G. Gribben, MD, Bercedis Peterson, PhD, Michael R. Grever, MD, Gerard Lozanski, MD, David M. Lucas, PhD, Richard A. Larson, MD, Michael A. Caligiuri, MD, Nyla A. Heerema, PhD
Journal: Blood
Blood (2004) 104 (11): 476.
https://doi.org/10.1182/blood.V104.11.476.476
Published: 2004